Business Description
Geovax Labs Inc
NAICS : 325412
SIC : 2834
ISIN : US3736786068
Total Employee Number:
19Description
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.23 | |||||
Equity-to-Asset | 0.17 | |||||
Debt-to-Equity | 0.8 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -95.41 | |||||
Beneish M-Score | -8.15 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.6 | |||||
3-Year EBITDA Growth Rate | 58.4 | |||||
3-Year EPS without NRI Growth Rate | 58.3 | |||||
3-Year FCF Growth Rate | 62.5 | |||||
3-Year Book Growth Rate | -82 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.06 | |||||
Quick Ratio | 1.06 | |||||
Cash Ratio | 0.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -191.4 | |||||
Shareholder Yield % | -270.77 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -2524.3 | |||||
Net Margin % | -2508.1 | |||||
EBITDA Margin % | -2501.88 | |||||
FCF Margin % | -2213.67 | |||||
OCF Margin % | -2212.31 | |||||
ROE % | -535.7 | |||||
ROA % | -331.43 | |||||
ROIC % | -3341.67 | |||||
3-Year ROIIC % | 920.19 | |||||
ROC (Joel Greenblatt) % | -4459.74 | |||||
ROCE % | -515.9 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.67 | |||||
PB Ratio | 5.35 | |||||
Price-to-Tangible-Book | 5.85 | |||||
EV-to-EBIT | -0.19 | |||||
EV-to-Forward-EBIT | 0.15 | |||||
EV-to-EBITDA | -0.19 | |||||
EV-to-Forward-EBITDA | 0.13 | |||||
EV-to-Revenue | 4.69 | |||||
EV-to-Forward-Revenue | 0.07 | |||||
EV-to-FCF | -0.21 | |||||
Earnings Yield (Greenblatt) % | -526.32 | |||||
FCF Yield % | -390.75 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Geovax Labs Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.739 | ||
| EPS (TTM) (€) | -18.633 | ||
| Beta | 0.1073 | ||
| 3-Year Sharpe Ratio | -1.19 | ||
| 3-Year Sortino Ratio | -1.16 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 93.525 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 93.525 - 93.525 | ||
| Shares Outstanding (Mil) | 5.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Geovax Labs Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Geovax Labs Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 | In 113 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 113 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-28 | In 5 days | ||
| Second quarter earnings results for 2026 | 2026-07-28 | In 5 days | ||
| General meeting for 2026 | 2026-06-17 08:30 | 93.53 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-14 | 93.53 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 93.53 (+0.00%) | ||
| Annual report for 2025 | 2026-04-14 | 93.53 (+0.00%) | ||
| 0.04:1 Stock Split | 2026-01-12 | 93.53 (+0.00%) | ||
| Third quarter earnings conference call for 2025 | 2025-11-13 | 93.53 (+0.00%) |
Show
Entries
Geovax Labs Inc Frequently Asked Questions
What is Geovax Labs Inc(STU:E8LA)'s stock price today?
The current price of STU:E8LA is €93.53. The 52 week high of STU:E8LA is €93.53 and 52 week low is €93.53.
When is next earnings date of Geovax Labs Inc(STU:E8LA)?
The next earnings date of Geovax Labs Inc(STU:E8LA) is 2026-07-28 Est..
Does Geovax Labs Inc(STU:E8LA) pay dividends? If so, how much?
Geovax Labs Inc(STU:E8LA) does not pay dividend.
Press Release
Articles on Geovax Labs Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers